Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

News

Research breakthrough shows insulin-producing cells can be regenerated

We could be one step closer to replacing the need for regular insulin injections in people living with type 1 diabetes, thanks to JDRF-funded research in Australia published this week in the Nature journal.
Breakthrough T1D profile picture
Breakthrough T1D staff 2 January 2024

Researcher Safiya Naina Marikar pipetting in the lab.

During the development of type 1, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This stops people with the condition being able to make their own insulin and means that they require lifelong insulin replacement therapy.

Replacing the damaged beta cells either from external sources or triggering the regeneration of beta cells within the body could potentially reduce or eliminate the need for insulin injections in individuals with type 1 diabetes.

We know that islet transplantation and whole pancreas replacement using donor tissues or organs reduces or removes the need for injecting insulin in those with type 1. However, the limited availability of donors, along with the need for life-long immunosuppression, make this option unsuitable for the majority of people living with the condition.

This is why finding ways to regenerate the body’s lost beta cells is so important.

What did the research find?

The research project, funded by JDRF and led by Professor Sam El-Osta from the Baker Heart and Diabetes Institute, investigated whether treatment with two drugs could regenerate insulin-producing cells in donor pancreases.

Using donor pancreases from a child and adult with type 1, and from a donor without type 1, the team demonstrated that pancreatic cells that don’t normally produce insulin – called ductal cells –could be made to behave like beta cells using two drugs known as EZH2 inhibitors (GSK 126 and Tazemetostat). Specifically, these newly generated beta-like cells were able to express genes that are associated with beta cells and, importantly, produce and secrete insulin.

The drug GSK126 is already FDA-approved for use in other diseases. The research project was the first time Tazemetostat has been used for this purpose.

These are incredibly exciting findings, as they suggest there is a pathway for people with type 1 to restore insulin production, potentially using cells from their own body. This method could remove the need for immunosuppressive treatments used with pancreas replacements and could address the issue of limited availability of donated islets needed for islet transplantation.

These therapies work in a different way to other therapies also being investigated which halt the immune system attack. These findings represent another avenue to tackle type 1 and enable everyone living with the condition to potentially achieve independence from round-the-clock insulin injections.

What’s next?

JDRF has been involved from an early stage of this research, with this breakthrough an extension of previous JDRF funded work also led by Professor El-Osta and his team.

Further work with pre-clinical models are now needed to take this research to the next stage. This is why we have already committed over £500,000 to extend this project.

You may also be interested in

Read more
A type 1 diabetes researcher on Dr Rocio Sancho's team, working in the lab

Our cure research

Find out about the innovative research we're funding to find cures for type 1 diabetes.

Read more
Sergio Pedraza, type 1 diabetes researcher, in the lab

Latest news

Get the latest about our research into preventing, treating and curing type 1 diabetes and our work to improve the lives of those living with it.

Read more
Two women wearing swimming caps in a swimming pool, fundraising for Breakthrough T1D UK

Get involved

Find out about the many ways you can raise money to fund type 1 diabetes research.

Connect with us on social

Related news

Read more
A young woman wearing a continuous glucose monitor looks on to a man scanning his sensor.
News
29 October 2024

New report calls for more equal access to type 1 diabetes technology

Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.

Read more
A researcher sits in a lab beside screening samples and lab equipment for early detection of type 1 diabetes.
Research
24 June 2024

New guidance sets out how to support people with early-stage type 1 diabetes

New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.

Read more
Would I Lie To You? Banner
Advocacy
1 February 2024

Our letter to the producers of Would I Lie to You?

We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.

Read more
A doctor talking to a young woman holding a pen
Policy and advocacy
23 January 2024

Parliamentary Inquiry calls for urgent action on type 1 and disordered eating

Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).